个人简介：

Dr Zhang has over 20 years of experience in both academic and commercial drug discovery establishments. His past roles include joint head of the biochemistry division of a multi-disciplinary academic drug discovery initiative at the Royal London Hospital. He was jointly responsible for a team of biochemists in studying the role of reperfusion injury and drug discovery in inflammatory diseases. In 1998 he became the head of a European pharmaceutical drug discovery establishment of Teijin Pharma, Japan. He focused on identifying and validating novel drugable targets in the fields of kidney and pulmonary fibrosis and COPD. He also helped Teijin Pharma to build up an extensive collaboration network in the UK.Since 2008 he has been working as the Business Development Executive for Asia/Pacific in MRC Technology. He is responsible for identifying and evaluating new business opportunities and for forging partnership deals with Pharma/Biotech companies in the Asia and Pacific region. He leads the MRCT initiative to penetrate China’s emerging economic powerhouse by helping build up a far-reaching network of useful contacts in China. He is responsible for the establishment of several high profile strategic collaborations between MRCT and top-tier research institutions in the Chinese Academy of Sciences.Dr Zhang has a wealth of experience and finely honed strategies in assessing and leveraging collaboration opportunities in research, technology transfer and RD development. He brought the first non-MRC drug target for fibrosis to MRCT discovery centre, which resulted in a successful multi-million pound deal with UCB in 2013. In 2014 he successfully led two multi-million pound out-licensing negotiations and deals to China.Dr Zhang has an excellent knowledge of the inner workings of both the West and China at the national and regional levels. He also has excellent bilingual and bicultural communication skills and an ability to sensitively source business intelligence to diplomatically handle the complexities that arise in building international collaborations.

公司简介：

MRC(英国国家医学研究院，Medical Research Council)成立于1913年，是英国政府性医学研究机构。 在过去的100多年中，MRC在国际医药领域取得了令人瞩目的成就，其中包括发现DNA双螺旋结构、单克隆抗体技术等重大成果，先后有29位科学家在MRC完成的成果获得诺贝尔奖。MRCT(Medical Research Council Technology)是MRC负责知识成果转化的机构，致力于将前沿科学研究发现转化为商业产品。MRCT的工作包括掌控和管理MRC的全部知识产权和技术转让，自主开发拥有独家知识产权的新药和技术，与制药公司共同进行后期开发等。MRCT目前已经与百健艾迪、罗氏、武田、默沙东等公司成功开发了药物上市。近期，MRCT还与优时比、辉瑞、阿斯利康、中科院上海细胞生物所、中科院生物物理所等企业机构在小分子、抗体药物等方面进行了合作。